LifeStance Health Group, Inc.(LFST)Stock Analysis
AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →13F Pro Quality Score
Rank #1,265 of 2,879 stocksTOP 50%
Rankings refresh quarterly once 80% of peers have filed (~45 days after quarter-end). Next update: ~Aug 14, 2026.
Revenue Growth
Profitability
Balance Sheet
Earnings Quality
Free Cash Flow
Institutional Flow
Revenue Scale
Dilution Risk
LFST Stock Analysis & AI Quality Score
AI stock analysis and institutional research for LifeStance Health Group, Inc. (LFST), a Healthcare sector company. 13F Pro's AI-powered ranking engine scores LFST at 53.7/100 on a 32-signal composite quality model, placing it at rank #1,265 of 2,879 stocks — the top half of the AI-ranked universe. LFST scores in the top quartile across revenue growth (76.3). Areas of concern include earnings quality (30.0) and institutional flow (36.8), which score below median versus the broader universe. Shareholder dilution risk is elevated at 25.2/100, reflecting ongoing share issuance or stock-based compensation. Based on the latest XBRL financial filings (Q1 2026), LifeStance Health Group, Inc. reports quarterly revenue of $403.5M, net income of $14.2M, an operating margin of 5.5%. Top institutional holders of LFST by reported 13-F value include TPG GP A,, FMR, SUMMIT PARTNERS L P, based on the most recent SEC filings. LFST trades on the Nasdaq exchange and files with the SEC under CIK 1845257. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate LFST daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for LifeStance Health Group, Inc. directly from SEC EDGAR.
Revenue
Q1 2026
$403.5M
Net Income
Q1 2026
$14.2M
Free Cash Flow
Q1 2026
$22.3M
Operating Margin
Q1 2026
5.5%
ROIC
Q1 2026
1.3%
D/E Ratio
Q1 2026
0.20
Revenue & Net Income
Earnings Per Share
Key Financials Over Time
Export Financial Table · Pro+Revenue
+13.9% YoYNet Income
+116.8% YoYOperating Income
+176.4% YoYTotal Assets
+4.0% YoYTotal Debt
+0.0% YoYOp. Cash Flow
+36.3% YoY| Metric | FY 2025 | FY 2024 | FY 2019 | FY 2018 |
|---|---|---|---|---|
| Revenue | $1.42B +13.9% | $1.25B +488.6% | $212.5M | — |
| Net Income | $9.7M +116.8% | $-57.4M -1113.3% | $5.7M | — |
| Operating Income | $24.1M +176.4% | $-31.6M -307.4% | $15.2M | — |
| Total Assets | $2.20B +4.0% | $2.12B | — | — |
| Total Debt | $297.3M +0.0% | $297.3M | — | — |
| Operating Cash Flow | $146.2M +36.3% | $107.3M +529.2% | $17.0M | — |
Get alerted when LFST's score changes
Free account: watchlist tracking, the daily AI brief, and the AI screener.
Available Research
13F Pro tracks comprehensive data for LifeStance Health Group, Inc. including:
Top Institutional Holders of LFST
TPG GP A, LLC
$892.0M140,026,557 shFMR LLC
$373.8M58,685,480 shSUMMIT PARTNERS L P
$186.1M29,209,776 shBlackRock, Inc.
$115.5M18,134,951 shDIMENSIONAL FUND ADVISORS LP
$66.0M10,367,680 shJENNISON ASSOCIATES LLC
$65.2M10,228,801 shVANGUARD PORTFOLIO MANAGEMENT LLC
$61.7M9,682,305 shVANGUARD CAPITAL MANAGEMENT LLC
$50.4M7,908,159 shSilversmith Partners I GP, LLC
$39.2M6,157,127 shUBS AM, a distinct business unit of UBS ASSET MANAGEMENT AME
$38.8M6,092,223 sh
| Fund | Value | Shares |
|---|---|---|
| TPG GP A, LLC | $892.0M | 140,026,557 |
| FMR LLC | $373.8M | 58,685,480 |
| SUMMIT PARTNERS L P | $186.1M | 29,209,776 |
| BlackRock, Inc. | $115.5M | 18,134,951 |
| DIMENSIONAL FUND ADVISORS LP | $66.0M | 10,367,680 |
| JENNISON ASSOCIATES LLC | $65.2M | 10,228,801 |
| VANGUARD PORTFOLIO MANAGEMENT LLC | $61.7M | 9,682,305 |
| VANGUARD CAPITAL MANAGEMENT LLC | $50.4M | 7,908,159 |
| Silversmith Partners I GP, LLC | $39.2M | 6,157,127 |
| UBS AM, a distinct business unit of UBS ASSET MANAGEMENT AME | $38.8M | 6,092,223 |
More Healthcare Companies
View all Healthcare →Put LFST on your watchlist
Track score changes the day LifeStance Health Group, Inc. files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.
Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).
Popular Research
Is LFST a good stock to buy?
13F Pro's AI-powered analysis of LifeStance Health Group, Inc. (LFST) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for LFST are available on the LFST stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing.
Which hedge funds own LFST?
Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling LFST. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of LifeStance Health Group, Inc.'s investment landscape.